Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021051 (
immunodeficiency
)
71,517
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of subchronic intracerebroventricular (i.c.v.) injection of the human
immunodeficiency
virus type 1 (HIV-1) recombinant protein gp120 (100 ng, given daily for up to 7 consecutive days) on cyclooxygenase type 2 (COX-2) expression was studied by immunohistochemistry in the brain of adult rats. In comparison to control, bovine serum albumin (100 ng, given i.c.v. for up to 7 days) treated animals (n = 6), a single daily injection of the viral protein for 7 consecutive days enhanced the number of COX-2 immunoreactive cells in the brain cortex of rats (n = 6 per group) and this was accompanied by a 50% increase over control
PGE2
content in whole brain tissue homogenates (n = 6). In another series of experiments, pretreatment of rats (n = 6) with indomethacin (6.0 mg/kg given i.p. 1 h before gp120 injection), an inhibitor COX activity, prevented apoptotic death typically produced by gp120 in the neocortex of rat suggesting that enhancement of COX-2 expression may be involved in the mechanisms of apoptosis yielded by the HIV-1 coat protein.
...
PMID:HIV-1 gp120-induced apoptosis in the rat neocortex involves enhanced expression of cyclo-oxygenase type 2 (COX-2). 953 50
Replication of human
immunodeficiency
virus type-1 (HIV-1) is highly dependent on the state of activation of the infected cells and is modulated by interactions between viral and host cellular factors.
Prostaglandin E2
(
PGE2
), a pleiotropic immunomodulatory molecule, is observed at elevated levels during HIV-1 infection as well as during the course of other pathogenic infections. In 1G5, a Jurkat-derived T cell line stably transfected with a luciferase gene driven by HIV-1 long terminal repeat (LTR), we found that
PGE2
markedly enhanced HIV-1 LTR-mediated reporter gene activity. Experiments have been conducted to identify second messengers involved in this
PGE2
-dependent up-regulating effect on the regulatory element of HIV-1. In this study, we present evidence indicating that signal transduction pathways induced by
PGE2
necessitate the participation of cyclic AMP, protein kinase A, and Ca2+. Experiments conducted with different HIV-1 LTR-based vectors suggested that
PGE2
-mediated activation effect on HIV-1 transcription was transduced via both NF-kappaB-dependent and -independent signaling pathways. The involvement of NF-kappaB in the
PGE2
-dependent activating effect on HIV-1 transcription was further confirmed using a kappaB-regulated luciferase encoding vector and by electrophoretic mobility shift assays. Results from Northern blot and flow cytometric analyses, as well as the use of a selective antagonist indicated that
PGE2
modulation of HIV-1 LTR-driven reporter gene activity in studied T lymphoid cells is transduced via the EP4 receptor subtype. These results suggest that secretion of
PGE2
by macrophages in response to infection or inflammatory activators could induce signaling events resulting in activation of proviral DNA present into T cells latently infected with HIV-1.
...
PMID:Prostaglandin E2 Up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappaB-dependent and -independent signaling pathways. 976 56
Secretory immunoglobulin A (IgA) is the principle antibody protecting against pathogens at mucosal sites. Ethanol (EtOH) exposure is related to adverse effects on the enterocyte cytoskeleton. The aim of this study was to assess the role of normal cytoskeletal function on IgA transcytosis and its modulation by EtOH by studying Madin-Darby canine kidney (MDCK) cells transfected with the polyimmunoglobulin receptor. MDCK cells were grown as confluent monolayers and treated with 5 per cent EtOH, cytochalasin D (Cyto-D, a cytoskeletal destabilizer), or pretreatment with prostaglandin E2 (a cytoskeletal stabilizer) followed by EtOH. Media alone served as control. IgA was then added to the basolateral side of the chambers, and apical samples were taken for enzyme-linked immunosorbent assay analysis at 0, 3, and 12 hours. Dimeric IgA transcytosis increased in all groups and was significantly depressed by 5 per cent EtOH and Cyto-D. Morphological slides revealed aggregation of actin after Cyto-D treatment.
Prostaglandin E2
prevented the decrease in IgA transcytosis seen otherwise with 5 per cent EtOH treatment. We conclude that IgA transcytosis is dependent on actin microfilaments of the cytoskeleton. Decreased IgA transport may lead to mucosal
immunodeficiency
and infectious complications after EtOH exposure.
...
PMID:Actin mediates secretory immunoglobulin A transport: effect of ethanol. 1235 47
MAIDS (murine AIDS) is caused by infection with the murine leukaemia retrovirus RadLV-Rs and is characterized by a severe
immunodeficiency
and T-cell anergy combined with a lymphoproliferative disease affecting both B- and T-cells. Hyperactivation of the cAMP-protein kinase A pathway is involved in the T-cell dysfunction of MAIDS and HIV by inhibiting T-cell activation through the T-cell receptor. In the present study, we show that MAIDS involves a strong and selective up-regulation of cyclo-oxygenase type 2 in the CD11b+ subpopulation of T- and B-cells of the lymph nodes, leading to increased levels of
PGE2
(prostaglandin E2).
PGE2
activates the cAMP pathway through G-protein-coupled receptors. Treatment with cyclo-oxygenase type 2 inhibitors reduces the level of
PGE2
and thereby reverses the T-cell anergy, restores the T-cell immune function and ameliorates the lymphoproliferative disease.
...
PMID:Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice. 1534 10
The protease inhibitor ritonavir is part of the highly active anti-retroviral therapy (HAART) successfully used in the treatment of human
immunodeficiency
virus (HIV)-1 infection. There is evidence that ritonavir alters intestinal permeability and induces damage to the small intestine. Because HIV infected patients taking HAART are at high risk for developing cardiovascular complications, there might be a need for the use of low dose of aspirin (ASA) to prevent ischemic events. Similarly, long term survival exposes HIV infected persons to detrimental interactions of ritonavir with non-steroidal anti-inflammatory drugs (NSAIDs). In the present work we tested whether ritonavir worsens intestinal injury caused by NSAIDs and ASA. C57BL6 mice were treated for 25 days with ritonavir and for a further 5 days with the combination of ritonavir plus ASA or ritonavir plus naproxen. In a second set of experiments C57BL6 mice were cotreated with ritonavir plus misoprostol, a PGE1 analog. We found that ritonavir administration caused intestinal damage and its co-administration with naproxen or ASA exacerbated the severity of injury and intestinal inflammation, as assessed by measuring haematocrit, MPO, mucosal levels of
PGE2
and mRNA levels of iNOS, MCP-1 and VLA-1. Co-administration of misoprostol protected against intestinal damage induced by naproxen and ritonavir. In conclusion we demonstrated that ritonavir causes intestinal damage and that its association with NSAIDs or ASA worsens the damage caused by COX-inhibitors. Misoprostol rescues from intestinal damage caused by ritonavir. Further studies are need to clarify whether this observation has a clinical readout.
...
PMID:In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 2431 32
Viral infections are a major cause of infectious diseases worldwide. Inflammation and the immune system are the major host defenses against these viral infection.
Prostaglandin E
2
(PGE
2
), an eicosanoid generated by cyclooxygenases, has been shown to modulate inflammation and the immune system by regulating the expression/concentration of cytokines. The effect of PGE
2
on viral infection and replication is cell type- and virus-family-dependent. The host immune system can be modulated by PGE
2
, with regards to immunosuppression, inhibition of nitrogen oxide (NO) production, inhibition of interferon (IFN) and apoptotic pathways, and inhibition of viral receptor expression. Furthermore, PGE
2
can play a role in viral infection directly by increasing the production and release of virions, inhibiting viral binding and replication, and/or stimulating viral gene expression. PGE
2
may also have a regulatory role in the induction of autoimmunity and in signaling via Toll-like receptors. In this review the known effects of PGE
2
on the pathogenesis of various infections caused by herpes simplex virus, rotavirus, influenza A virus and human
immunodeficiency
virus as well the therapeutic potential of PGE
2
are discussed.
...
PMID:Prostaglandin E
2
As a Modulator of Viral Infections. 2826 Nov 11
<< Previous
1
2